Tvardi Therapeutics, Inc. (TVRD)

Tvardi Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	4.97	4.46	2.8	2.73
Research & Development	23.04	23.65	15.87	18.47
Operating Expenses	28.01	28.11	18.67	21.19
Operating Income	-28.01	-28.11	-18.67	-21.19
Interest Expense	-	-	-	-0
Interest & Investment Income	0.78	0.75	1.32	0.65
Other Non Operating Income (Expenses)	-7.54	-2.04	-	-
Pretax Income	-34.77	-29.4	-17.35	-20.54
Net Income	-34.77	-29.4	-17.35	-20.54
Net Income to Common	-34.77	-29.4	-17.35	-20.54
Shares Outstanding (Basic)	6	6	6	6
Shares Outstanding (Diluted)	6	6	6	6
Shares Change (YoY)	0.43%	0.31%	0.09%	-
EPS (Basic)	-5.43	-4.59	-2.72	-3.22
EPS (Diluted)	-5.43	-4.59	-2.72	-3.22
Free Cash Flow	-21.86	-18.31	-21.04	-17.92
Free Cash Flow Per Share	-3.42	-2.86	-3.30	-2.81
EBITDA	-27.92	-28.01	-18.57	-21.11
D&A For EBITDA	0.1	0.1	0.1	0.09
EBIT	-28.01	-28.11	-18.67	-21.19

Source: S&P Global Market Intelligence. Standard template. Financial Sources.